Table 1 The recent clinical trials targeting CSCs or CSC-associated pathways
From: Characteristics of the cancer stem cell niche and therapeutic strategies
Pathway | Agent | Tumor type | Phase | Study number |
|---|---|---|---|---|
EMT | Plerixafor | Pancreatic cancer | Phase 2 | NCT04177810 |
Multiple myeloma | Phase 4 | NCT05087212 | ||
Eribulin | Breast cancer | Phase 1 | NCT02120469 | |
Phase 2 | NCT04517292 | |||
GI-6301 | Chordoma | Phase 2 | NCT02383498 | |
Vorinostat | T-cell lymphoma | Phase 3 | NCT01728805 | |
Fresolimumab | Breast cancer | Phase 2 | NCT01401062 | |
Hypoxia | Temsirolimus | Renal cell carcinoma | Phase 1 | NCT00700258 |
CRLX101 | Prostate cancer | Phase 2 | NCT03531827 | |
Renal cell carcinoma | Phase 2 | NCT02187302 | ||
Notch | PF-03084014 | Desmoid tumors | Phase 2 | NCT04195399 |
Breast cancer | Phase 1 | NCT01876251 | ||
LY3039478 | Solid tumors | Phase 1 | NCT02836600 | |
MK-0752 | Breast cancer | Phase 4 | NCT00756717 | |
Tarextumab | Solid tumors | Phase 1 | NCT01277146 | |
CB-103 | Advanced cancers | Phase 1/2 | NCT03422679 | |
Wnt | PRI-724 | PDAC | Phase 1 | NCT01764477 |
DKN-01 | Biliary tract cancer | Phase 1 | NCT04057365 | |
Gastric cancer | Phase 2 | NCT04363801 | ||
Liver cancer | Phase 1/2 | NCT03645980 | ||
Vantictumab | Breast cancer | Phase 1b | NCT01973309 | |
CWP232291 | Acute myeloid leukemia | Phase 1/2 | NCT03055286 | |
Hedgehog | Vismodegib | Basal cell carcinoma | Phase 2 | NCT02667574 |
Chondrosarcomas | Phase 2 | NCT01267955 | ||
Meningiomas | Phase 2 | NCT02523014 | ||
Medulloblastoma | Phase 2 | NCT01878617 | ||
Itraconazole | Esophageal cancer | Phase 2 | NCT04481100/NCT04018872 | |
Prostate cancer | Phase 1/2 | NCT03513211 | ||
Taladegib | Solid tumors | Phase 2 | NCT05199584 |